N-([(4-chlorophenyl)amino]carbonyl)-4-(1-methylethyl)benzenesulfonamide | 102607-97-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-([(4-chlorophenyl)amino]carbonyl)-4-(1-methylethyl)benzenesulfonamide
• 英文别名: 1-(4-Chlorophenyl)-3-(4-propan-2-ylphenyl)sulfonylurea
• CAS: 102607-97-6
• 化学式: C₁₆H₁₇ClN₂O₃S
• 分子量: 352.842
• InChiKey: VBVLROPWKZDSIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-异丙基苯磺酰胺 、 对氯苯异氰酸酯 在 sodium hydroxide 作用下， 以 丙酮 为溶剂， 以89%的产率得到N-([(4-chlorophenyl)amino]carbonyl)-4-(1-methylethyl)benzenesulfonamide
  参考文献：
  名称：

  Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships

  摘要：

  A series of diarylsulfonylureas with exceptionally broad-spectrum activity against syngeneic rodent solid tumors in vivo is described. Their discovery resulted from a program dedicated to in vivo screening for novel oncolytics in solid tumor models, rather than traditional ascites leukemia models. The structures, oral efficacy, side-effect profile, and mechanism of action of these sulfonylureas appear to be distinct from previously known classes of oncolytics. An extensive series of analogues was prepared to probe structure-activity relationships (SAR), with particular focus on the substituent patterns of each aryl domain. Quantitative analysis of these substituent SARs, using the method of cluster significance analysis, showed the lipophilicity of the substituents to be the dominant determinant of activity. One compound from the series, LY186641 (104, sulofenur), has progressed to Phase I clinical trials as an antitumor drug.

  DOI：

  10.1021/jm00171a013

文献信息

• Improvements in or relating to benzenesulfonamido derivatives
  申请人：ELI LILLY AND COMPANY

  公开号：EP0166615A2

  公开（公告）日：1986-01-02

  This invention provides the use of certain benzenesulfonamide derivatives of the formula (I) wherein: R, and R3 are independently hydrogen, C,-C3 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; R2 is halo, methyl, or trifluoromethyl; and R4 is hydrogen, halo, methyl, ortrifluoromethyl, in the treatment of susceptible neoplasms in mammals. Also provided are certain novel benzenesulfonamide derivatives and their pharmaceutical formulations.

  本发明提供了式(I)的某些苯磺酰胺衍生物的用途，其中：R和R3独立地为氢、C,-C3烷基、卤代、三氟甲基或C1-C3烷氧基；R2为卤代、甲基或三氟甲基；R4为氢、卤代、甲基或三氟甲基，用于治疗哺乳动物的易感肿瘤。 还提供了某些新型苯磺酰胺衍生物及其药物制剂。
• HOWBERT, J. JEFFRY;GROSSMAN, C. SUE;CROWELL, THOMAS A.;RIEDER, BRENT J.;H+, J. MED. CHEM., 33,(1990) N, C. 2393-2407
  作者：HOWBERT, J. JEFFRY、GROSSMAN, C. SUE、CROWELL, THOMAS A.、RIEDER, BRENT J.、H+

  DOI：——

  日期：——
• US4845128A
  申请人：——

  公开号：US4845128A

  公开（公告）日：1989-07-04
• US5110830A
  申请人：——

  公开号：US5110830A

  公开（公告）日：1992-05-05
• US5260338A
  申请人：——

  公开号：US5260338A

  公开（公告）日：1993-11-09